Premier Biomedical, Inc. (BIEI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Premier Biomedical, Inc. (BIEI) trades at $0.00 with AI Score 46/100 (Grade C). Premier Biomedical, Inc. is a research-focused company developing innovative medical offerings, specifically topical pain management solutions incorporating hemp oil. Market cap: $649,988, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for BIEI: BIEI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIEI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BIEI: the 1 perspectives are evenly split.
How is this calculated? →Premier Biomedical, Inc. (BIEI) Healthcare & Pipeline Overview
Premier Biomedical, Inc. is a Knoxville-based research company established in 2010, specializing in the development and identification of innovative medical offerings. The firm primarily focuses on formulating and disseminating topical pain management solutions that incorporate hemp oil, operating within the biotechnology sector to address unmet medical needs.
What Is the Investment Thesis for BIEI?
Premier Biomedical, Inc. presents an investment thesis centered on its research-driven approach within the biotechnology sector, specifically targeting the topical pain management market with hemp oil solutions. The company's innovative focus on addressing unmet medical needs could represent a significant value driver if its product pipeline progresses successfully through clinical development and regulatory approval. With a market capitalization of 650K and a Beta of 0.74, the company is in an early, highly speculative stage, indicating potential for substantial upside if milestones are met, but also significant risk. Key catalysts include advancements in clinical trials, successful navigation of regulatory pathways for its hemp-based products, and securing future funding to sustain its research and development efforts. Investors must closely monitor the company's progress in these areas, as its OTC Other listing inherently carries risks associated with thinly traded securities and limited disclosure, making due diligence critical for assessing its long-term viability and potential for commercialization.
Based on FMP financials and quantitative analysis
BIEI Key Highlights
- Market Capitalization: $0.00B, reflecting its status as a micro-cap or pre-revenue stage company.
- Beta: 0.74, suggesting the stock has historically exhibited lower volatility compared to the broader market.
- Employee Count: Operates with a lean team of 4 employees, indicating a focused research and development structure.
- Dividend Policy: Does not currently distribute dividends to shareholders.
- Operational Focus: Primarily engaged in the research, genesis, and identification of innovative medical offerings, with a specific emphasis on topical pain management solutions utilizing hemp oil.
Who Are BIEI's Competitors?
BIEI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| CGEM Cullinan Therapeutics, Inc. | $17.81 | +1.02% | $1.09B | 46 |
| AIXC AIxCrypto Holdings, Inc. | $1.12 | +1.82% | $5.78M | 46 |
| LFMDP LifeMD, Inc. | $23.20 | -0.73% | $158.20M | 46 |
| ALBBY Alibaba Health Information Technology Limited | $8.00 | +0.00% | $6.45B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIEI's Key Strengths?
- Focused research and development efforts in the growing topical pain management market.
- Innovative approach to medical offerings, particularly utilizing hemp oil.
- Lean operational structure with a small, dedicated team of 4 employees.
- Addresses unmet medical needs within the pain management sector.
What Are BIEI's Weaknesses?
- Micro-cap status with a 650K market capitalization, indicating early-stage and high risk.
- OTC Other listing, implying higher inherent risks, limited liquidity, and reduced transparency.
- Limited employee base (4 employees) which may constrain extensive R&D and commercialization efforts.
- Significant reliance on securing future funding to advance its research pipeline and operations.
What Could Drive BIEI Stock Higher?
- Progress in research and development efforts for its innovative topical pain management solutions.
- Potential initiation or advancement of clinical trials for its medical offerings, providing data on efficacy and safety.
- Pursuit and achievement of regulatory approvals for its hemp oil-based products, opening pathways for commercialization.
- Securing additional funding through private placements, grants, or strategic partnerships to support its research pipeline and operational needs.
- Continued development of innovative medical offerings aimed at addressing specific unmet needs within the healthcare sector.
What Are the Key Risks for BIEI?
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Inherent risks associated with thinly traded securities and speculative ventures typical of the OTC Other market.
- Failure to secure sufficient future funding necessary for sustained research, development, and potential commercialization efforts.
- Negative outcomes, delays, or outright failures in clinical trials for its medical technologies, impacting product viability.
- Inability to obtain necessary regulatory approvals for product commercialization, preventing market entry.
- Intense competition within the biotechnology and pain management sectors from larger, more established companies.
What Are the Growth Opportunities for BIEI?
- Growth opportunity 1: **Expansion in the Topical Pain Management Market**: The global market for pain management is experiencing significant growth, driven by an aging population and a societal shift towards non-opioid and localized treatment options. Premier Biomedical's focus on topical pain management solutions, particularly those incorporating hemp oil, positions it to potentially capitalize on this expanding demand. As consumer and medical acceptance of hemp-derived products increases, the company could see a substantial market for its innovative formulations, especially if they demonstrate superior efficacy and safety profiles compared to existing alternatives. This market trend offers a long-term growth runway.
- Growth opportunity 2: **Advancements in Hemp Oil Formulation and Delivery**: Ongoing research into optimizing the bioavailability, stability, and efficacy of hemp oil in topical applications represents a significant growth opportunity. Premier Biomedical's dedicated research efforts in this area could lead to the development of proprietary, advanced formulations that offer enhanced therapeutic benefits. Such advancements could result in stronger intellectual property, superior product performance, and a competitive edge, allowing the company to capture a larger share of the specialized pain relief market as scientific understanding and technological capabilities evolve over the next 3-5 years.
- Growth opportunity 3: **Successful Regulatory Pathway Navigation**: Achieving regulatory approvals for its topical pain management solutions is a critical growth catalyst. Successful navigation of regulatory processes, such as securing FDA clearance or similar international approvals, would validate the safety and efficacy of its products. This would transition the company from a pure R&D entity to one capable of commercializing its innovations, unlocking significant market access and revenue potential. The timeline for such approvals is typically multi-year, but each successful step would de-risk the investment and open new market segments.
- Growth opportunity 4: **Strategic Partnerships and Licensing Agreements**: Given its lean operational structure and research focus, forming strategic partnerships with larger pharmaceutical companies, consumer health brands, or distribution networks presents a substantial growth opportunity. These collaborations could provide Premier Biomedical with essential capital, accelerate product development, and offer immediate access to broader distribution channels and established marketing infrastructure. Licensing its proprietary formulations or technologies could generate revenue streams without the need for extensive internal commercialization efforts, significantly expanding its market reach within a 2-4 year timeframe.
- Growth opportunity 5: **Diversification of Medical Offerings**: While currently focused on topical pain management, Premier Biomedical's broader mandate of 'genesis and identification of innovative medical offerings' suggests potential for pipeline diversification. Leveraging its research capabilities, the company could explore other therapeutic areas, diagnostic tools, or medical technologies beyond its current scope. This strategic expansion could open new market segments, reduce reliance on a single product category, and provide multiple avenues for growth, potentially creating new revenue streams over a 5-10 year horizon as new research initiatives mature.
What Opportunities Does BIEI Have?
- Expanding market for non-opioid and hemp-based pain solutions globally.
- Potential for strategic partnerships or licensing agreements to accelerate development and market reach.
- Successful navigation of regulatory pathways for product commercialization, unlocking significant revenue potential.
- Diversification into other therapeutic areas leveraging its core R&D capabilities and expertise.
What Threats Does BIEI Face?
- Intense competition from established pharmaceutical and biotechnology companies with greater resources.
- Significant regulatory hurdles and potential adverse changes in legislation concerning hemp-derived products.
- Failure to secure adequate funding, which could halt research, development, and commercialization efforts.
- Risk of clinical trial failures or lack of demonstrated efficacy in product development, leading to project termination.
What Are BIEI's Competitive Advantages?
- Proprietary research and development processes for identifying and formulating innovative medical offerings.
- Specialized focus on hemp oil-based topical pain management solutions, potentially leading to unique formulations.
- Potential for intellectual property protection (patents) on its specific product formulations or delivery methods.
- Early-stage positioning in niche areas of hemp-derived therapeutics, allowing for focused expertise development.
What Does BIEI Do?
Premier Biomedical, Inc. was founded on May 10, 2010, by Mitchell S. Felder, establishing its central operations in Knoxville, Tennessee. The company functions as a research-intensive entity, actively engaged in both the genesis and identification of innovative medical offerings. Its core focus is directed toward formulating and disseminating topical pain management solutions, specifically those that integrate hemp oil. This specialization positions Premier Biomedical within the broader biotechnology sector, where it aims to develop and commercialize medical technologies. The company's operational pipeline includes ongoing research into various therapies and diagnostics, reflecting its commitment to addressing unmet medical needs through scientific innovation. As a lean organization with 4 employees, Premier Biomedical emphasizes a focused approach to product development, aiming to bring novel solutions to market. Its strategic intent is to leverage research and development capabilities to create value in the healthcare landscape, particularly within the growing segment of alternative pain management. The company's journey since its inception has been characterized by a dedication to exploring new frontiers in medical science, with a clear emphasis on its hemp oil-based topical solutions as a primary commercialization pathway.
What Products and Services Does BIEI Offer?
- Conducts research for innovative medical offerings.
- Identifies new medical solutions and technologies.
- Formulates topical pain management solutions.
- Disseminates specialized topical pain management products.
- Incorporates hemp oil as a key ingredient in its pain management formulations.
- Operates within the biotechnology sector, focusing on medical technology development.
- Aims to address unmet medical needs through its research and product pipeline.
How Does BIEI Make Money?
- Engages in the research and development of proprietary medical technologies and formulations.
- Seeks to commercialize its developed topical pain management solutions, particularly those utilizing hemp oil.
- Focuses on securing necessary regulatory approvals to bring its innovative products to market.
- Potentially generates revenue through the sale of its medical products or by licensing its intellectual property to other entities.
What Industry Does BIEI Operate In?
Premier Biomedical, Inc. operates within the dynamic Healthcare sector, specifically positioned in the Medical - Pharmaceuticals industry with a focus on biotechnology. The company's niche in topical pain management, particularly with hemp oil, places it within a rapidly evolving market segment driven by increasing demand for non-opioid pain solutions and growing acceptance of cannabis-derived therapeutics. The global pain management market is substantial and continues to expand, fueled by an aging population and a rise in chronic conditions. BIEI's innovative approach aims to address unmet medical needs, differentiating itself from larger pharmaceutical companies that may focus on traditional drug development. The competitive landscape includes established pharmaceutical giants, specialized biotech firms, and numerous smaller companies exploring cannabinoid-based therapies. Premier Biomedical's success hinges on its ability to carve out a distinct position through effective R&D and successful commercialization in this competitive and highly regulated environment.
Who Are BIEI's Key Customers?
- Currently, its primary 'customer' is its internal research and development pipeline.
- Future potential customers include patients seeking effective topical pain relief.
- Healthcare providers, such as physicians and specialists, who prescribe or recommend pain management solutions.
- Pharmacies, retail outlets, and online platforms that distribute healthcare products.
Net buyingInsider Activity
The most recent 12 insider filings for Premier Biomedical, Inc. break down as 0 sales and 12 purchases. On net that is roughly 20.7M shares acquired (about $18K) — insiders putting money in tends to read as conviction.
BIEI Valuation & Market Position
With a 650K market cap, Premier Biomedical, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BIEI's quantitative score of 46/100 is below the peer average of 60/100.
ROE 3%Key Financial Metrics
Return on equity for Premier Biomedical, Inc. stands at 3.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -7.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 0/9Financial Health
Premier Biomedical, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Premier Biomedical, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Knoxville, US. The company is led by CEO David Caplan. BIEI has traded publicly since 2012.
BIEI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively as discussions around Premier Biomedical's innovative treatments gain traction.
- There has been a notable increase in media coverage highlighting the company's advancements, which often translates to heightened investor interest.
- The overall market's focus on biotech and healthcare innovations creates a favorable environment for companies like Premier Biomedical.
Bear Case
- Concerns remain about the company's financial stability, as ongoing funding challenges may impact its ability to execute on projects.
- Community sentiment still reflects skepticism, with some investors worried about the timeline for product development and market entry.
- Recent regulatory hurdles have raised questions about the feasibility of bringing new treatments to market, adding to investor anxiety.
- Market perception remains cautious due to the volatility typically associated with biotech stocks, which can deter risk-averse investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
BIEI Latest News
-
Premier Graphene Eyes Space and Aerospace Applications
globenewswire.com · Jun 23, 2026
-
Premier Graphene Inc. (OTC: BIEI) Currently Anticipates Reporting First Profitable Quarter in Company History
prismmediawire.com · Jun 18, 2026
-
Premier Graphene Inc. and Affiliate HGI Industrial Technologies Secure Two New Mexican Military Contracts, Advancing Defense Revenue Strategy
globenewswire.com · Jun 10, 2026
-
Premier Graphene Successfully Completes Initial Military Order
Yahoo! Finance: BIEI News · May 12, 2026
BIEI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIEI.
Price Targets
Wall Street price target analysis for BIEI.
BIEI MoonshotScore
What does this score mean?
The MoonshotScore rates BIEI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Premier Graphene Eyes Space and Aerospace Applications
Premier Graphene Inc. (OTC: BIEI) Currently Anticipates Reporting First Profitable Quarter in Company History
Premier Graphene Inc. and Affiliate HGI Industrial Technologies Secure Two New Mexican Military Contracts, Advancing Defense Revenue Strategy
Premier Graphene Successfully Completes Initial Military Order
Leadership: David Caplan
Chief Executive Officer
David Caplan serves as the Chief Executive Officer of Premier Biomedical, Inc., where he is responsible for managing the company's operations and strategic direction. While specific details regarding his prior career history, educational background, or previous executive roles are not publicly available, his current position involves overseeing a lean team of 4 employees. His leadership is critical in guiding the company's research and development initiatives within the biotechnology sector, particularly its focus on innovative medical offerings and hemp oil-based pain management solutions.
Track Record: Specific achievements and strategic decisions under David Caplan's leadership are not detailed in the provided information. However, his tenure is marked by the company's continued focus on research and development in topical pain management solutions incorporating hemp oil. He is responsible for managing the company's limited resources and guiding its efforts to identify and develop innovative medical offerings, aiming to advance its pipeline through early-stage development.
BIEI OTC Market Information
Premier Biomedical, Inc. trades on the OTC Other tier, which represents the lowest and most speculative segment of the OTC market. Unlike major exchanges such as NYSE or NASDAQ, which impose stringent listing requirements regarding financial health, market capitalization, and disclosure, the OTC Other tier has minimal to no such standards. Companies in this tier often have limited public information, making comprehensive due diligence challenging for investors. This environment is typically associated with highly speculative ventures, micro-cap companies, and those that may not meet the reporting requirements of higher OTC tiers like OTCQB or OTCQX, leading to increased risk and uncertainty.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and financial transparency, hindering comprehensive investor analysis.
- Extremely low trading volume and poor liquidity, making it difficult to buy or sell shares.
- High volatility and increased susceptibility to price manipulation due to thin trading.
- Difficulty in obtaining reliable valuation metrics or analyst coverage.
- Potential for the stock to cease trading or be delisted without significant notice.
- Verify the company's current operational status and the legitimacy of its research projects.
- Scrutinize any available financial statements for completeness, accuracy, and red flags.
- Thoroughly research the background and track record of CEO David Caplan and other key personnel.
- Assess the scientific backing and commercial viability of its hemp oil-based product claims.
- Investigate any past or pending litigation, regulatory actions, or compliance issues.
- Understand the evolving regulatory environment for hemp-derived medical products.
- Confirm the existence and strength of any intellectual property, such as patents or trademarks.
- Established founding date of May 10, 2010, indicating a decade-plus operational history.
- Specific focus on research and development in a defined medical area (topical pain management with hemp oil).
- Identifiable headquarters in Knoxville, Tennessee, suggesting a physical operational base.
- Known CEO (David Caplan) and a stated employee count (4), providing some organizational structure.
Premier Biomedical, Inc. Healthcare Stock: Key Questions Answered
What does Premier Biomedical, Inc. do?
Premier Biomedical, Inc. is a research-focused company dedicated to the genesis and identification of innovative medical offerings. Its primary business revolves around the formulation and dissemination of topical pain management solutions that incorporate hemp oil. Operating within the biotechnology sector from its Knoxville, Tennessee headquarters, the company aims to develop and commercialize medical technologies, including therapies and diagnostics, to address unmet medical needs. This involves extensive research and development to create novel products for the healthcare market, particularly targeting the growing demand for alternative pain relief options.
How does Premier Biomedical, Inc. navigate regulatory approval processes for its hemp-based products?
Premier Biomedical, Inc.'s navigation of regulatory approval processes for its hemp-based products is a critical and complex undertaking. The regulatory landscape for hemp-derived medical solutions is still evolving, requiring careful adherence to guidelines set by bodies like the FDA. While specific details of BIEI's regulatory track record or pending approvals are not disclosed, the company would need to conduct rigorous clinical trials to demonstrate the safety and efficacy of its topical pain management solutions. Successful data generation and meticulous submission of regulatory dossiers are paramount to obtaining market authorization, a process that can be lengthy and resource-intensive for a company of its size.
What are the primary financial and operational challenges for Premier Biomedical, Inc. as an OTC Other company?
As an OTC Other listed company with a 650K market capitalization, Premier Biomedical, Inc. faces significant financial and operational challenges. Financially, its micro-cap status implies limited access to capital markets, making it difficult to secure the substantial funding required for extensive research, clinical trials, and potential commercialization. Operationally, with only 4 employees, the company operates with extremely lean resources, which can constrain the scope and pace of its R&D efforts. The OTC Other listing further exacerbates these challenges by contributing to low liquidity, high stock volatility, and limited public disclosure, making it difficult to attract institutional investment and sustain long-term growth without significant external capital injections.
What are the key factors to evaluate for BIEI?
Premier Biomedical, Inc. (BIEI) holds an AI score of 46/100 (low). Not financial advice.
How frequently does BIEI data refresh on this page?
BIEI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BIEI's recent stock price performance?
Premier Biomedical, Inc. (BIEI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused research and development efforts in the growing topical pain management market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIEI overvalued or undervalued right now?
Valuing Premier Biomedical, Inc. (BIEI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BIEI?
Before investing in Premier Biomedical, Inc. (BIEI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on the provided text and may not represent the full scope of the company's operations or financial standing. Specific details regarding clinical trial stages, regulatory timelines, and market sizes for BIEI's products are not available in the source data and have been discussed generally.